The past month has been a busy time for the HealthTech Activator (HTA), with our In-depth Market Validation pilot programme coming to a successful conclusion. We also continue to build further offerings, including several new workshops later this year that will be announced in future emails and shared on our website. In the meantime, contact us for more information about our database and research support services.
Check out the news and links below to hear more about what’s been happening at the HTA, and across NZ healthtech, over the past month.
________________________________________________________________________________________________________________________________________________________________________
From March to July 2021, five healthtech businesses working with Callaghan Innovation participated in an In-Depth Market Validation pilot programme, covering several phases of work aimed to support their commercialisation journey.
The pilot involved workshops, remote coaching, and interviews to help companies validate their markets. The five companies received insights from the HTA’s Global Data offering, access to GLG expert interviews, and other network support from the HTA and NZTE.
On the 5th of July, we held a showcase for the companies to present the value they derived from the pilot and the next steps on their journey. The showcase was a resounding success and the feedback the HTA received has informed the development of the next programme.
The HTA will open expressions of interest for the Feb 2022 In-Depth Market Validation cohort in September. Keep an eye out for updates, and contact us if you’d like further information, including accessing Global Data and GLG Insights for validating your market.
_______________________________________________________________________________
Clinical validation is central to medical device development, but there’s more to consider than just the regulator’s requirements. Kieran Jina of Pacific Channel talks about how market and stakeholder validation is not only key to understanding your commercial opportunity; it is also key to designing a clinical development programme.
_______________________________________________________________________________
________________________________________________________________________________________________________________________________________________________________________
New Zealand’s $2.85b healthtech sector
Brandon Capital leads $14m investment to develop new cancer drug (NBR)
Aroa Biosurgery reveals new surgical product in development for 2023 (NBR)
.png)
